Richter Jumps as U.S. Approval Ends Years of Waiting for DrugBy and
Cariprazine sales in U.S. may help offset declines in Europe
Ipopema analyst sees Richter sales jumping up to 30% by 2019
Hungarian drugmaker Gedeon Richter Nyrt., hit by eroding sales in some of its European markets, headed for the biggest gain in five months after U.S. authorities granted approval for an anti-psychotic drug developed jointly with Allergan Plc.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.